John G. Nutt
#112,031
Most Influential Person Now
John G. Nutt's AcademicInfluence.com Rankings
John G. Nuttphilosophy Degrees
Philosophy
#4740
World Rank
#7364
Historical Rank
Logic
#2136
World Rank
#3060
Historical Rank
John G. Nuttbiology Degrees
Biology
#6257
World Rank
#8931
Historical Rank
Neuroscience
#747
World Rank
#779
Historical Rank
Download Badge
Philosophy Biology
John G. Nutt's Degrees
- Doctorate Medicine Stanford University
Why Is John G. Nutt Influential?
(Suggest an Edit or Addition)John G. Nutt's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease (2006) (940)
- Freezing of gait: moving forward on a mysterious clinical phenomenon (2011) (930)
- Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1 (1994) (729)
- Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease (2010) (702)
- Human walking and higher‐level gait disorders, particularly in the elderly (1993) (616)
- Impaired mesial frontal and putamen activation in Parkinson's disease: A positron emission tomography study (1992) (612)
- The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. (1984) (551)
- A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. (2002) (547)
- Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. (2005) (540)
- Postural inflexibility in parkinsonian subjects (1992) (491)
- Levodopa motor complications in Parkinson's disease (2000) (483)
- Epidemiology of focal and generalized dystonia in Rochester, Minnesota (1988) (437)
- iTUG, a Sensitive and Reliable Measure of Mobility (2010) (422)
- Strategies to advance translational research into brain barriers (2008) (414)
- Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. (2006) (383)
- Levodopa-induced dyskinesia: review, observations, and speculations. (1990) (370)
- Direction-specific postural instability in subjects with Parkinson's disease (2005) (366)
- Parkinson's disease (2004) (341)
- Effects of dopamine on postural control in parkinsonian subjects: scaling, set, and tone. (1996) (334)
- Step initiation in Parkinson's disease: Influence of levodopa and external sensory triggers (1997) (332)
- Localisation in PET Images: Direct Fitting of the Intercommissural (AC—PC) Line (1989) (324)
- The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson's disease (2009) (301)
- The response to levodopa in parkinson's disease: Imposing pharmacological law and order (1996) (301)
- A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. (2014) (294)
- Diagnosis and Initial Management of Parkinson's Disease (2005) (283)
- Levodopa Is a Double‐Edged Sword for Balance and Gait in People With Parkinson's Disease (2015) (263)
- Freezing of gait: a practical approach to management (2015) (262)
- CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. (2008) (261)
- Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients (1994) (258)
- Trunk accelerometry reveals postural instability in untreated Parkinson's disease. (2011) (251)
- A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD (2010) (244)
- Exacerbated physical fatigue and mental fatigue in Parkinson's disease (2001) (238)
- Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease (2010) (234)
- Environmental antecedents of young‐onset Parkinson's disease (1993) (232)
- Pharmacokinetics of levodopa. (1984) (230)
- Knee trembling during freezing of gait represents multiple anticipatory postural adjustments (2009) (224)
- Increased risk of Parkinson's disease in parents and siblings of patients (1994) (215)
- Asymmetric pedunculopontine network connectivity in parkinsonian patients with freezing of gait. (2013) (202)
- Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene GRIN2A as a Parkinson's Disease Modifier Gene via Interaction with Coffee (2011) (200)
- The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile (2008) (187)
- Postural muscle responses to multidirectional translations in patients with Parkinson's disease. (2004) (186)
- Framework for understanding balance dysfunction in Parkinson's disease (2013) (182)
- Postural sway as a marker of progression in Parkinson's disease: a pilot longitudinal study. (2012) (180)
- Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility (1988) (176)
- On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics (1987) (174)
- Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study) (2004) (172)
- Functional Reorganization of the Locomotor Network in Parkinson Patients with Freezing of Gait (2014) (166)
- Treatment of Parkinson’s disease with trophic factors (2008) (157)
- Verbal Fluency Task Affects Gait in Parkinson's Disease with Motor Freezing (1998) (156)
- Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at‐home testing device (2009) (155)
- Combination of Dynamic and Integral Methods for Generating Reproducible Functional CBF Images (1990) (152)
- Clinical practice. Diagnosis and initial management of Parkinson's disease. (2005) (152)
- Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients (1986) (151)
- Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease (2007) (150)
- Continuous dopamine-receptor stimulation in advanced Parkinson's disease (2000) (148)
- The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism (1985) (147)
- Multiple balance tests improve the assessment of postural stability in subjects with Parkinson’s disease (2005) (147)
- Motor fluctuations and dyskinesia in Parkinson's disease. (2001) (146)
- Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk (2008) (145)
- Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. (2001) (142)
- LONG-TERM TREATMENT OF PARKINSONISM WITH BROMOCRIPTINE (1978) (141)
- Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease (1995) (137)
- Family caregiving (1998) (136)
- Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. (2012) (134)
- Peripheral pharmacokinetics of apomorphine in humans (1989) (132)
- Axial hypertonicity in Parkinson's disease: Direct measurements of trunk and hip torque (2007) (131)
- Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients (2007) (130)
- Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. (1992) (129)
- Centrally initiated postural adjustments in parkinsonian patients on and off levodopa. (2000) (129)
- Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism (2008) (128)
- Levodopa improves physical fatigue in Parkinson's disease: A double‐blind, placebo‐controlled, crossover study (2003) (124)
- Pharmacological treatment in Parkinson's disease: Effects on gait. (2016) (123)
- Continuous monitoring of turning in Parkinson's disease: Rehabilitation potential. (2015) (121)
- LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. (2006) (121)
- Placebo influences on dyskinesia in Parkinson's disease (2008) (120)
- Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients (1987) (116)
- Profile of families with parkinsonism‐predominant spinocerebellar ataxia type 2 (SCA2) (2004) (116)
- Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease (2010) (113)
- Autosomal dominant episodic ataxia: A heterogeneous syndrome (1986) (113)
- Evolution of the response to levodopa during the first 4 years of therapy (2002) (112)
- Epidemiology of dystonia in Rochester, Minnesota. (1988) (108)
- Duodenal and gastric delivery of levodopa in parkinsonism (1988) (108)
- The dopamine transporter: Importance in Parkinson's disease (2004) (108)
- Reduced performance in balance, walking and turning tasks is associated with increased neck tone in Parkinson's disease (2009) (108)
- Episodic ataxias as channelopathies (1995) (108)
- An alternative clinical postural stability test for patients with Parkinson’s disease (2006) (104)
- Short‐ and long‐duration responses to levodopa during the first year of levodopa therapy (1997) (104)
- Glycoproteomics in neurodegenerative diseases. (2010) (103)
- Long-duration response to levodopa (1995) (102)
- Assessing mobility at home in people with early Parkinson's disease using an instrumented Timed Up and Go test. (2011) (101)
- ABT‐431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease (1999) (101)
- A gene for episodic ataxia/myokymia maps to chromosome 12p13. (1994) (98)
- Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study (2006) (96)
- Axial kinesthesia is impaired in Parkinson's disease: Effects of levodopa (2010) (95)
- Exploring gene-environment interactions in Parkinson’s disease (2008) (94)
- Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics (2006) (93)
- Postural muscle tone in the body axis of healthy humans. (2006) (93)
- Milestones in gait, balance, and falling (2011) (91)
- Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease (1997) (90)
- Apomorphine infusional therapy in parkinson's disease: Clinical utility and lack of tolerance (1995) (89)
- Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: Preliminary findings (1995) (89)
- 3‐O‐Methyldopa and the response to levodopa in Parkinson's disease (1987) (88)
- SCA2 may present as levodopa‐responsive parkinsonism (2003) (87)
- Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease. (2002) (86)
- The clinical significance of freezing while turning in Parkinson’s disease (2017) (86)
- Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments (2006) (86)
- Effects of Group, Individual, and Home Exercise in Persons With Parkinson Disease: A Randomized Clinical Trial (2015) (85)
- Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease (1989) (85)
- Can stooped posture explain multidirectional postural instability in patients with Parkinson’s disease? (2005) (85)
- Inhibition, executive function, and freezing of gait. (2014) (84)
- Does an inhibitory action of levodopa contribute to motor fluctuations? (1988) (83)
- Dual task interference on postural sway, postural transitions and gait in people with Parkinson's disease and freezing of gait. (2017) (83)
- Motor subtype in Parkinson's disease: Different disorders or different stages of disease? (2016) (82)
- Analyzing 180° turns using an inertial system reveals early signs of progression of parkinson's disease (2009) (82)
- A case‐control study of twin pairs discordant for Parkinson's disease (1986) (82)
- Identification of two new KCNA1 mutations in episodic ataxia/myokymia families. (1995) (81)
- A comparison of fenfluramine and amphetamine in man (1975) (79)
- Which dyskinesia scale best detects treatment response? (2013) (75)
- Using Modafinil to Treat Fatigue in Parkinson Disease: A Double-Blind, Placebo-Controlled Pilot Study (2009) (74)
- DBS and diathermy interaction induces severe CNS damage (2001) (74)
- Classification of gait and balance disorders. (2001) (74)
- Substance P in human cerebrospinal fluid (1980) (74)
- Neurological disorders of gait, balance and posture: a sign-based approach (2018) (73)
- Dual-task interference and brain structural connectivity in people with Parkinson's disease who freeze (2014) (71)
- Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: Differing effects of brief and continued practice (2000) (71)
- Errors in postural preparation lead to increased choice reaction times for step initiation in older adults. (2011) (71)
- Methadone‐naloxone mixtures for use in methadone maintenance programs; I. An evaluation in man of their pharmacological feasibility; II. Demonstration of acute physical dependence (1974) (70)
- Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa? (2007) (69)
- Clinical and biochemical studies with controlled‐release levodopa/carbidopa (1986) (69)
- Classification, diagnosis, and etiology of gait disorders. (2001) (69)
- Pharmacokinetics and pharmacodynamics of levodopa (2008) (69)
- Absorption of apomorphine by various routes in parkinsonism (1991) (68)
- Higher‐level gait disorders: An open frontier (2013) (68)
- Preparation for compensatory forward stepping in Parkinson's disease. (2010) (67)
- Balance and Gait Represent Independent Domains of Mobility in Parkinson Disease (2016) (66)
- A locus for the nystagmus-associated form of episodic ataxia maps to an 11-cM region on chromosome 19p. (1995) (66)
- Freezing of gait is associated with a mismatch between motor imagery and motor execution in narrow doorways, not with failure to judge doorway passability (2011) (65)
- Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation (2007) (64)
- Parkinsonism syndrome in heterozygotes for Niemann–Pick C1 (2013) (61)
- Genetic association between α‐synuclein and idiopathic parkinson's disease (2008) (60)
- The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications. (2011) (60)
- Thrombocytopenia associated with sodium valproate treatment (1979) (60)
- Effects of thalamic stimulation on tremor, balance, and step initiation: A single subject study (1993) (59)
- Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes (1997) (59)
- Levodopa Reduces Muscle Tone and Lower Extremity Tremor in Parkinson’s Disease (1995) (57)
- Preferences of Patients With Parkinson’s Disease for Communication About Advanced Care Planning (2015) (57)
- Quantifying freezing of gait in Parkinson's disease during the instrumented timed up and go test (2012) (57)
- Age at onset of Parkinson disease and apolipoprotein E genotypes. (2002) (56)
- Neuroimmunophilin ligands in the treatment of Parkinson's disease. (2002) (55)
- Effect of an opiate antagonist on movement disorders. (1978) (54)
- Exploring Outcome Measures for Exercise Intervention in People with Parkinson's Disease (2013) (54)
- Abnormal force patterns for multidirectional postural responses in patients with Parkinson’s disease (2004) (53)
- The Effects of Different Repeated Doses of Entacapone on the Pharmacokinetics of L-Dopa and on the Clinical Response to L-Dopa in Parkinson's Disease (2001) (53)
- Levodopa normalizes exercise related cortico-motoneuron excitability abnormalities in Parkinson's disease (2003) (52)
- Objective Gait and Balance Impairments Relate to Balance Confidence and Perceived Mobility in People With Parkinson Disease (2016) (50)
- Quantifying effects of age on balance and gait with inertial sensors in community-dwelling healthy adults (2016) (49)
- Impaired mesial frontal and putamen activation in Parkinson's disease :a PET study (1992) (49)
- Clinical pharmacology of levodopa-induced dyskinesia. (2000) (49)
- Measuring freezing of gait during daily-life: an open-source, wearable sensors approach (2021) (48)
- Methylphenidate Increases the Motor Effects of L-Dopa in Parkinson's Disease: A Pilot Study (2001) (48)
- Apomorphine can sustain the long-duration response to l-DOPA in fluctuating PD (2000) (47)
- Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. (1989) (46)
- Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. (2014) (46)
- Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. (2012) (46)
- Objective measurement of dyskinesia in Parkinson's disease using a force plate (2010) (45)
- Response to levodopa treatment in dopa-responsive dystonia. (2001) (44)
- The effect of deep brain stimulation randomized by site on balance in Parkinson's disease (2014) (43)
- Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease (1998) (43)
- Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease. (2019) (43)
- Analysis of the α-synuclein G209A mutation in familial Parkinson's disease (1998) (42)
- Treatment of Huntington disease with a cholinergic agonist (1978) (41)
- Mood response to levodopa infusion in early Parkinson's disease. (1998) (41)
- Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations (1988) (41)
- Motor fluctuations in parkinson's disease (1989) (41)
- Dyskinesia and the antiparkinsonian response always temporally coincide (2010) (40)
- Effect of brief levodopa holidays on the short‐duration response to levodopa (1994) (40)
- SENSORY SYMPTOMS IN PARKINSONISM RELATED TO CENTRAL DOPAMINERGIC FUNCTION (1984) (39)
- Lid abnormalities secondary to cerebral hemisphere lesions (1977) (39)
- Piloting the NPF data-driven quality improvement initiative. (2010) (39)
- Time course of tolerance to apomorphine in parkinsonism (1992) (39)
- Comorbidity and functional mobility in persons with Parkinson disease. (2014) (38)
- Diurnal responsiveness to apomorphine (1987) (38)
- Lithium: effects on subjective functioning and morphine-induced euphoria. (1977) (38)
- Assessment of the ability of open- and closed-loop cueing to improve turning and freezing in people with Parkinson’s disease (2018) (38)
- How to Select Balance Measures Sensitive to Parkinson’s Disease from Body-Worn Inertial Sensors—Separating the Trees from the Forest (2019) (37)
- Short-term paroxetine treatment does not alter the motor response to levodopa in PD (2005) (37)
- Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. (2007) (36)
- The effect of exercise on levodopa absorption (1992) (36)
- Lack of evidence for an association between UCHL1 S18Y and Parkinson’s disease (2007) (35)
- Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson’s disease and matched controls during daily living (2020) (35)
- Continuous Assessment of Gait Velocity in Parkinson's Disease from Unobtrusive Measurements (2007) (35)
- Buspirone in Parkinson's disease. (1986) (34)
- “Silly Walks” in Parkinson's disease: Unusual presentation of dopaminergic‐induced dyskinesias (2011) (33)
- Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. (2000) (33)
- Cranial dystonia (1984) (32)
- Parkinson’s disease, CYP2D6 polymorphism, and age (2001) (31)
- Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. (1988) (31)
- Long-term 24-hour duodenal infusion of levodopa: Outcome and dose requirements (2006) (31)
- GDNF in treatment of Parkinson's disease: response to editorial (2006) (30)
- Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease. (2010) (30)
- Trial of dextromethorphan/quinidine to treat levodopa‐induced dyskinesia in Parkinson's disease (2017) (30)
- Disease progression, drug action and Parkinson’s disease: Why time cannot be ignored (2008) (29)
- Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson’s Disease (2005) (29)
- Cognitively Challenging Agility Boot Camp Program for Freezing of Gait in Parkinson Disease (2020) (29)
- Importance of Within Subject Variation in Levodopa Pharmacokinetics: A 4Year Cohort Study in Parkinson’s Disease (2005) (29)
- Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease (2012) (28)
- Differences in the Motor Response to Apomorphine Between Untreated and Fluctuating Patients With Parkinson's Disease (1992) (28)
- Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease (1992) (28)
- Anticholinergic therapies in the treatment of Parkinson's disease (2002) (28)
- Speech therapy in Parkinson's disease (2002) (28)
- Dual tasking during postural stepping responses increases falls but not freezing in people with Parkinson's disease. (2014) (28)
- Modeling the Short- and Long-Duration Responses to Exogenous Levodopa and to Endogenous Levodopa Production in Parkinson's Disease (2004) (27)
- Blepharospasm and oromandibular dystonia (Meige's syndrome) in sisters (1981) (27)
- AUTOIMMUNITY IN STIFF MAN SYNDROME (1988) (27)
- CONTROL OF MEDICALLY REFRACTORY RESTLESS LEGS SYNDROME WITH INTRATHECAL MORPHINE: CASE REPORT (2008) (27)
- Treatment with tryptophan of levodopa-associated psychiatric disturbances. (1980) (26)
- Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson’s Disease (2020) (26)
- Long-term l-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease (2003) (26)
- Higher level gait disorders (2007) (25)
- Does tolerance develop to levodopa? Comparison of 2‐and 21‐h levodopa infusions (1993) (25)
- Digital Biomarkers of Mobility in Parkinson's Disease During Daily Living. (2020) (25)
- Laboratory versus daily life gait characteristics in patients with multiple sclerosis, Parkinson’s disease, and matched controls (2020) (24)
- Induction by Dopamine D 1 Receptor Agonist ABT-431 of Dyskinesia Similar to Levodopa in Patients With Parkinson Disease (2001) (24)
- A novel X‐linked four‐repeat tauopathy with Parkinsonism and spasticity (2010) (23)
- Interpreting the results of Parkinson's disease clinical trials: Time for a change (2011) (23)
- Levodopa: Rational and irrational pharmacology (1994) (23)
- Associations between mobility, cognition and callosal integrity in people with parkinsonism (2016) (23)
- Effects of the agility boot camp with cognitive challenge (ABC-C) exercise program for Parkinson’s disease (2020) (22)
- Life-sustaining treatment orders, location of death and co-morbid conditions in decedents with Parkinson's disease. (2015) (22)
- The short‐duration response to apomorphine: Implications for the mechanism of dopaminergic effects in parkinsonism (1990) (22)
- Effect of augmenting cholinergic function on gait and balance (2015) (21)
- L‐Dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys (1990) (21)
- Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy (2020) (21)
- Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease. (2006) (20)
- Performance of a motor task learned on levodopa deteriorates when subsequently practiced off (2014) (20)
- Recovery from Multiple APAs Delays Gait Initiation in Parkinson’s Disease (2017) (20)
- Investigation of Anticipatory Postural Adjustments during One-Leg Stance Using Inertial Sensors: Evidence from Subjects with Parkinsonism (2017) (20)
- Apomorphine tolerance in Parkinson's disease: lack of a dose effect. (1996) (19)
- Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. (1994) (19)
- Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: PHARMACODYNAMICS OF LEVODOPA IN PARKINSON'S DISEASE (1995) (19)
- Amantadine and other antiglutamate agents (2002) (19)
- Cognitive function in people with and without freezing of gait in Parkinson’s disease (2020) (19)
- Monozygotic twins with Parkinson's disease (1986) (19)
- The effect of L‐dopa infusions with and without phenylalanine challenges in parkinsonian patients (1993) (19)
- Gait Stability Has Phase-Dependent Dual-Task Costs in Parkinson’s Disease (2018) (19)
- Foot-Tapping Rate as an Objective Outcome Measure for Parkinson Disease Clinical Trials (2009) (19)
- Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients. (1992) (18)
- Levodopa in human breast milk Clinical implications (1998) (18)
- Pharmacodynamics of levodopa in Parkinson's disease. (1995) (18)
- Gait and balance disorders (2002) (17)
- The relationship between obsessive‐compulsive symptoms and PARKIN genotype: The CORE‐PD study (2015) (17)
- Treatment of depression in idiopathic Parkinson's disease (2002) (17)
- Mobility, mood and site of care impact health related quality of life in Parkinson's disease. (2014) (16)
- Focal cranial dystonia. (1983) (16)
- parkin mutation analysis in clinic patients with early-onset Parkinson [corrected] disease. (2004) (16)
- Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA. (1996) (16)
- Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease. (2019) (16)
- Basal ganglia, Parkinson's disease and levedopa therapy (2000) (16)
- Aromatic L‐Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease (2020) (15)
- Lisuride treatment of focal dystonias (1985) (15)
- Deep Brain Stimulation May Improve Quality of Life in People With Parkinson's Disease Without Affecting Caregiver Burden (2014) (15)
- Peering through the FoG: Visual manipulations shed light on freezing of gait (2012) (14)
- Effect of Bout Length on Gait Measures in People with and without Parkinson’s Disease during Daily Life (2020) (14)
- Drugs to treat dementia and psychosis (2002) (14)
- MAO‐B inhibitors for the treatment of Parkinson's disease (2002) (13)
- Effect of expectancy and personality on cortical excitability in Parkinson's disease (2013) (13)
- Post‐Traumatic Shoulder Movement Disorders: A Challenging Differential Diagnosis Between Organic and Functional (2014) (13)
- Linear Relationship between Plasma Concentration and Dosage of Sodium Valproate (1979) (12)
- Discussion of Research Priorities for Gait Disorders in Parkinson's Disease (2021) (12)
- Response to l-dopa in PD (2000) (12)
- Hand coordination as a quantitative measure of motor abnormality and therapeutic response in Parkinson’s disease (2007) (12)
- ACTIONS OF BROMOCRIPTINE IN THE SHY – DRAGER AND STEELE – RICHARDSON – OLSZEWSKI SYNDROMES (1979) (12)
- Impaired perception of surface tilt in progressive supranuclear palsy (2017) (11)
- Teaching program for the Unified Dyskinesia Rating Scale (2009) (11)
- The Impact Of Freezing Of Gait On Balance Perception And Mobility In Community-Living With Parkinson’S Disease (2018) (11)
- Effect of cholinergic agents in Huntington's disease (1983) (10)
- Responsiveness of Objective vs. Clinical Balance Domain Outcomes for Exercise Intervention in Parkinson's Disease (2020) (10)
- Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. (2008) (10)
- Lateralized Connectivity between Globus Pallidus and Motor Cortex is Associated with Freezing of Gait in Parkinson’s Disease (2020) (10)
- 15.17 Compensatory step deficits in Parkinson's disease: An inability to select motor programs (2005) (10)
- Dyskinesias assessment workshop: reports from the working groups. (1999) (10)
- Fluctuations in response to treatment for Parkinson's disease. (2001) (9)
- Are Cholinesterase Inhibitors Effective in Improving Balance in ParkinsonsDisease (2016) (9)
- Letters to the editor (1990) (9)
- OFF–off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease (2006) (9)
- Apraxia of gait- or apraxia of postural transitions? (2018) (9)
- Drugs to treat autonomic dysfunction in Parkinson's disease (2002) (9)
- parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism (2005) (9)
- Dyskinesia Induced by Levodopa and Dopamine Agonists in Patients with Parkinson's Disease (2008) (9)
- Surgical treatment for Parkinson's disease: Deep brain surgery (2002) (8)
- Management of parkinsonism and treatment of associated complications. (1995) (8)
- Erratum: Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease (Annals of Neurology (2006) 59 (459-466)) (2006) (8)
- Ergot Derivatives for Parkinsonism (1978) (8)
- A unified dyskinesias rating scale for L-dopa-induced dyskinesias? (1999) (7)
- Dual-Task Costs of Quantitative Gait Parameters While Walking and Turning in People with Parkinson's Disease: Beyond Gait Speed. (2020) (7)
- Non-Dopaminergic Therapies (2018) (7)
- Cognitive function in people with and without freezing of gait in Parkinson’s disease (2020) (7)
- LOWERED ERYTHROCYTE-SEDIMENTATION RATE WITH SODIUM VALPROATE (1978) (7)
- Effect of sodium valproate on parkinsonism and L-DOPA induced dyskinesia (1980) (6)
- Pharmacokinetics and pharmacodynamics of levodopa clinical implications (1992) (6)
- Meige syndrome: treatment with trihexyphenidyl. (1983) (6)
- Surgical treatment for Parkinson's disease: Neural transplantation (2002) (6)
- Tolerance to apomorphine develops and reverses rapidly (2010) (6)
- PHARMACODYNAMICS AND DRUG ACTION (1992) (6)
- A Two-Stage Tremor Detection Algorithm for Wearable Inertial Sensors During Normal Daily Activities (2019) (6)
- Psychosocial counseling in Parkinson's disease (2002) (6)
- Catechol O-methyltransferase inhibition and the treatment of Parkinson's disease. (1998) (6)
- DA agonists ‐ Non‐Ergot derivaties: Ropinirole (2002) (6)
- DA agonists ‐ Ergot derivaties: Cabergoline (2002) (6)
- Parkin mutation analysis in clinic patients with early‐onset Parkinson's disease (Am J Med Genet 129A: 44–50, 2004) (2005) (6)
- Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease (2021) (6)
- A wrinkle in ON-time - A GI structural abnormality confounding levodopa therapy with Duodopa rescue; a case study. (2018) (5)
- Autoimmune etiology for cranial dystonia. (1990) (5)
- Joubert syndrome surviving to adulthood associated with a progressive movement disorder (2007) (5)
- Low doses of apomorphine transiently reduce locomotor activity in MPTP-treated mice (2007) (5)
- Physical and occupational therapy in Parkinson's disease (2002) (5)
- Case Studies in Neuroscience: A dissociation of balance and posture demonstrated by camptocormia. (2018) (5)
- Cortical thickness as predictor of response to exercise in people with Parkinson's disease (2020) (5)
- DA agonists ‐ Non‐Ergot derivaties: Apomorphine (2002) (4)
- Functional limits of stability and standing balance in people with Parkinson's disease with and without freezing of gait using wearable sensors. (2021) (4)
- Changes in prefrontal cortical activity and turning in response to dopaminergic and cholinergic therapy in Parkinson's disease: A randomized cross-over trial. (2021) (4)
- Comparison of intravenously administered methadone (ME), morphone (MO), heroin (H) and placebo (P) (1973) (4)
- How is balance controlled by the nervous system? (2020) (4)
- Parkinsonism: Candidate Disorder for Implanted Pumps? (1988) (3)
- Treatment of Huntington disease with a direct cholinergic agonist (1978) (3)
- Reply: Does dominant pedunculopontine nucleus exist? (2015) (3)
- Exclusion of dominant mutations within the FTDP-17 locus on chromosome 17 for Parkinson's disease (1999) (3)
- Assessment of an Objective Method of Dyskinesia Measurement in Parkinson's Disease (2018) (3)
- The effect of γ-vinyl GABA on amphetamine stereotypy in rats (1980) (3)
- DA agonists ‐ Ergot derivaties: Lisuride (2002) (3)
- Abnormalities of Posture and Movement (1990) (3)
- Comorbidity and Functional Mobility in Persons with (2014) (3)
- Inertial Sensor Algorithms to Characterize Turning in Neurological Patients With Turn Hesitations (2020) (3)
- Stepping up to meet the challenge of freezing of gait in Parkinson’s disease (2022) (2)
- The Pharmacokinetics of L-DOPA in Plasma and CSF of the Monkey (1991) (2)
- Longitudinal monitoring of gait and mobility in Parkinson's disease (PD) using an instrumented timed up and go test (iTUG) (2009) (2)
- Parkinson disease: Deep brain stimulation versus best medical therapy for PD (2010) (2)
- Does the natural history of transient ischemic attacks (TIAs) justify surgery? (1983) (2)
- A 10-year follow-up--genotypic analysis disproves phenotypic classification. (1997) (2)
- Parkinson's disease: evaluation and therapeutic strategy. (1987) (1)
- The effect of γ-vinyl GABA on stereotypy in rats (1979) (1)
- Continuous levodopa infusion is better—for now (2015) (1)
- falls in an elderly man caused by orthostatic negative myoclonus : 1517 (2014) (1)
- DA agonists ‐ Non‐Ergot derivaties: Pramipexole (2002) (1)
- Does the natural history of transient ischemic attacks (TIAs) justify surgery (1983) (1)
- How are postural responses to external perturbations affected by PD? (2020) (1)
- Effect of Levodopa and Environmental Setting on Gait and Turning Digital Markers Related to Falls in People with Parkinson's Disease (2022) (1)
- Authors' response to Marras and Oakes, 'Piecing together the puzzle of progression and mortality in Parkinson's disease'. (2013) (1)
- Relationship Between Brain Volumes and Objective Balance and Gait Measures in Parkinson's Disease. (2021) (1)
- Resting state functional networks predict different aspects of postural control in Parkinson's disease. (2022) (1)
- P2.113 Multicenter, randomized, double-blind, sham surgery-controlled study of intraputaminal AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD) (2009) (1)
- Lithium (Li): Lack of effect on morphine (MS) euphoria (1973) (1)
- What is the function of carbidopa in the treatment of Parkinsonism (1983) (1)
- New pharmacological and surgical therapies for Parkinson's disease. (1998) (1)
- Clinical pharmacology of levodopa-induced dyskinesia. Discussion (2000) (1)
- Does the Dose of Carbidopa Matter? A Randomized Clinical Trial in Parkinson's Disease (S02.006) (2012) (1)
- DA agonists ‐ Ergot derivaties: Dihydroergocryptine (DHEC) (2002) (1)
- Acute effects of scopolamine in Huntington's disease. (1983) (1)
- Unified Dyskinesia Rating Scale (2016) (1)
- DA agonists ‐ Non‐Ergot derivaties: Piribedil (2002) (1)
- Cerebrospinal fluid (CSF) neurotransmitters in the stiff man syndrome (1979) (1)
- Effects of the agility boot camp with cognitive challenge (ABC-C) exercise program for Parkinson’s disease (2020) (1)
- Balance Dysfunction in Parkinson's Disease (2019) (1)
- O.002 Piloting the NPF data-driven quality initiative to improve Parkinson's disease management (2009) (0)
- Exploring the effects of dopamine on sensorimotor inhibition and mobility in older adults (2022) (0)
- Longitudinal monitoring of gait and mobility in Parkinson's Disease using an instrumented version of the timed up and go test (2009) (0)
- Relating Response Inhibition, Brain Connectivity, and Freezing of Gait in People with Parkinson’s Disease (2020) (0)
- Is freezing of gait a balance disorder? (2020) (0)
- Neurodegeneration and the Brain Barriers Contributors (2007) (0)
- Turning Back the Clock in Parkinson's Disease: Practical Recommendations for Managing Diurnal Symptom Worsening. (2021) (0)
- GABA-ergic systems in parkinsonism (1979) (0)
- Approach To Treatment Of Depression In Parkinson’s Disease: Results from NPF-QII (P7.073) (2014) (0)
- Diuretic activity of a new narcotic antagonist in man (Bristol compound 2605) (1973) (0)
- Future perspectives on balance disorders in PD (2020) (0)
- Reply (1995) (0)
- Case Studies in Neuroscience : 1 A Dissociation of Balance and Posture Demonstrated by 2 Camptocormia 3 4 (2017) (0)
- Treatment of Fluctuations and Dyskinesia (2002) (0)
- Clinical disorders of balance, posture and gait (1997) (0)
- Patients On and Off Levodopa Centrally Initiated Postural Adjustments in Parkinsonian (2013) (0)
- Capturing Innovation and Living with Risk (2002) (0)
- DA agonists ‐ Overview (2002) (0)
- P2.067 Resolving mode-of-inheritance and association of PRKN with PD in a comprehensive sequence and copy-number-variation (CNV) analysis of 3800 subjects (2009) (0)
- Geriatric Neurological Gait Disorders (2017) (0)
- Clinical and Genetic Characteristics of Participants with Juvenile PD: The CORE-PD Study (IN10-2.001) (2012) (0)
- Gait disorders (1994) (0)
- Measuring freezing of gait during daily-life: an open-source, wearable sensors approach (2021) (0)
- Effects of a Cognitively Challenging Agility Boot Camp Program on Balance and Gait in People With Parkinson’s Disease: Does Freezing of Gait Status Matter? (2022) (0)
- Reply to: “Letter on Discussion of Gait Research” (2022) (0)
- Gait and turning characteristics from daily life increase ability to predict future falls in people with Parkinson's disease (2023) (0)
- Explorer Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson ' s disease (2017) (0)
- Influence offluctuations ofplasma large neutral amino acids withnormal diets on theclinical responseto levodopa (1989) (0)
- DA agonists ‐ Ergot derivaties: Bromocriptine (2002) (0)
- Prescribed Gait Tests Versus Continuous Monitoring of Gait in People With Parkinson’s Disease (2016) (0)
- Drugs to treat gastrointestinal motility problems (2002) (0)
- Gait Ignition Failure (2010) (0)
- P06.5 The effects of rTMS of different frequency and intensity on cortical excitability and finger tapping in PD (2006) (0)
- Laboratory versus daily life gait characteristics in patients with multiple sclerosis, Parkinson’s disease, and matched controls (2020) (0)
- How is balance during quiet stance affected by PD? (2020) (0)
- Parkinson’s Disease Patients’ Preferences for Communication About Advanced Care Planning (P7.303) (2014) (0)
- 168 THE EFFECTS OF PARKINSON'S DISEASE AND A CONCURRENT COGNITIVE TASK ON VOLUNTARY AND COMPENSATORY STEPPING (2010) (0)
- Why is balance so important in Parkinson disease? (2020) (0)
- The effect of a cholinesterase inhibitor on balance in Parkinson’s disease (P6.047) (2015) (0)
- No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison of Multiple Scales (P04.187) (2013) (0)
- The effect of raising brain GABA on an animal model of hyperkinesia (1980) (0)
- 持続性ドパミン刺激(CDS)--レボドパの運動合併症に対する解決策か? (2007) (0)
- 781 Bilateral Intraputaminal Infusion of Liatermin (Glial Cell Line-derived Neurotrophic Factor r-metHuGDNF) in Subjects with Advanced Parkinson's Disease (2004) (0)
- treatmentsa diagnostic test and specific syndrome/myalgic encephalomyelitis: disease Current research priorities in chronic fatigue (2007) (0)
- PATIENTS WITH PARKINSONʼS DISEASE PERSEVERATE POSTURAL ADJUSTMENTS FOR COMPENSATORY STEPPING (1998) (0)
- How are anticipatory postural adjustments in preparation for voluntary movements affected by PD? (2020) (0)
- PARKINSON'S DISEASE DYSKINESIAS. AUTHOR'S REPLY (1994) (0)
- Reply: Does dominant pedunculopontine nucleus exist? Probably not. (2015) (0)
- Letters to the editor (1997) (0)
- Chapter 18 – Gait and Balance (2007) (0)
- Comparison between the GAITRite and a new, portable kinematic system on detecting gait alterations in early Parkinson's Disease (2008) (0)
- Re: Gait disorders (1994) (0)
- Assessment of the ability of open- and closed-loop cueing to improve turning and freezing in people with Parkinson’s disease (2018) (0)
- The case of the freezing man (2008) (0)
- 189 COGNITIVE TASK AFFECTS TURNING MORE THAN STRAIGHT WALKING IN EARLY STAGES OF PARKINSON'S DISEASE (2010) (0)
- Parkinson's disease dyskinesias (1994) (0)
- How and why is turning affected by Parkinson disease? (2020) (0)
- Variation of Patient-Reported Outcomes (PDQ-39) in a Cross-Sectional Analysis of the NPF QII- Research Registry (P06.066) (2012) (0)
- Does Cueing Need Attention? A Pilot Study in People with Parkinson’s Disease (2022) (0)
- Drugs to treat urinary frequency, urgency, and/or urge incontinence (2002) (0)
- The Blood-Brain Barrier and Movement Disorders (1989) (0)
- NSAIDs and the control of hypertension: A pilot study (1992) (0)
- How is dynamic balance during walking affected by PD? (2020) (0)
- Effect of GABA agonists on an animal model of spasticity (1980) (0)
- Cortical excitability and physical fatigability in Parkinson's disease - a 12-month longitudinal study (2008) (0)
- Reply: Continuous stimulation: Is it the answer to the motor complications of levodopa (2008) (0)
- The case for and concerns about continuous dopamine stimulation in Parkinson's disease. (1988) (0)
- How should the clinician approach imbalance in PD? (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With John G. Nutt?
John G. Nutt is affiliated with the following schools:
